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Abstract
Health claims for probiotics are evaluated by the Panel on Dietetic Products, Nutrition and Allergies of the European Food Safety Authority.
Despite a substantial amount of basic and clinical research on the beneficial effects of probiotics, all of the evaluated claim applications
thus far have received a negative opinion. With the restrictions on the use of clinical endpoints, validated biomarkers for gut health
and immune health in relation to reduction in disease risk are needed. Clear-cut criteria for design as well as evaluation of future studies
are needed. An open dialogue between basic and clinical scientists, regulatory authorities, food and nutrition industry, and consumers
could bridge the gap between science and marketing of probiotics.
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The European Regulation on Nutrition and Health Claims of
2006(1) provides a common regulation allowing health claims
to be made on foods in a uniform manner throughout the
member states in the European Union (EU). The main objectives
of the EU regulation were to ensure a high level of consumer
protection, to allow effective functioning of the internal
market within the EU, to increase legal security for economic
operators, fair competition within the food and nutrition indus-
try, and stimulation and protection of innovations in the food
sector. When fully implemented, only health claims obtained
on the community list of permitted health claims will be allowed
within the EU. The European Food Safety Authority (EFSA) has
received 4637 health claim submissions, of which 8 % deal with
probiotics when the existing health claims were submitted by
the member states in 2007. The current situation (November
2010) is that the Panel on Dietetic Products, Nutrition and
Allergies (NDA) of EFSA has expressed a negative opinion on
all of the claims on probiotics evaluated thus far. Thus, the
objectives of the regulation are invalidated with respect to
probiotics: rejection of all claims does not improve consumer
protection, hinders cross-border movements of goods, has a
negative impact on the willingness of companies to invest
in research and development, and does not stimulate fair
competition. Most importantly, the objective of protecting
consumers is not met. The consumer does not receive adequate
information on probiotics, in which a considerable amount of
research and development has been invested.
Health claims for food (including probiotics) can be
submitted under either article 13 or 14. Claims that relate to
growth, development and function of the body (including
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immune function); psychological and behavioural functions;
or weight management belong to article 13, and claims that
relate to a reduction in disease risk or refer to children’s
development and health must be submitted under article 14.
Health claims related to article 13.1 must be based on gen-
erally accepted scientific evidence. When based on newly
developed scientific evidence, the claims belong to article
13.5, which may include protection of proprietary data.
Probiotics are defined as ‘live micro-organisms which, when
administered in adequate amounts, confer a health benefit on
the host’(2). The health claim is already incorporated in the
definition of probiotics: confer a health benefit. Thus, as
long as the consumer would take in adequate amounts and
the micro-organisms are alive, a generic health claim could
be made, as long as a benefit has been demonstrated.
The WHO definition of probiotics is the favoured one,
because it is used by the US Food and Drug Administration,
recommended by the International Scientific Association for
Probiotics and Prebiotics and is used in the majority of the
scientific publications. It is stated that the use of the term ‘pro-
biotic’ in itself thus corresponds to a health claim but is not
acceptable by EFSA, as the claimed effect is not measurable(3).
Over the last two decades, there has been a growing interest
on both basic and clinical science in probiotics. This has
resulted in more than 6000 publications in the biomedical litera-
ture, with over 60 % published since 2008 including articles in
the highest-ranking medical and basic scientific journals.
With regard to the clinical and nutritional application of
probiotics, guidelines have been proposed to establish and sub-
stantiate their beneficial effects, including design of randomised
clinical trials(4). The PASSCLAIM project was carried out to
define the normal function of the gut and immune system and
describe available methods of measuring this function(5). A
great number of well-designed and well-conducted trials have
been published, substantiating the beneficial effects of (specific
strains of) probiotics on risk reduction and management of a
variety of diseases and conditions. When performing a literature
search on probiotics, PubMed suggests to use diarrhoea, irrita-
ble bowel, immune, prevention, treatment, allergy, clostridium,
intestinal and ulcerative as additional search terms. For the
combination of key words ‘probiotics’, ‘clinical trial’ and
‘human’, over 750 publications are listed, many of which are
published in top ranking nutrition and clinical journals. The
translation of this considerable amount of basic and clinical
research into practical conclusions (and approved health
claims) apparently goes wrong. Why? At present, there are
gaps between biomedical science and regulatory requirements
for getting a health claim approved. In this paper, we will illus-
trate some of the gaps that prevent approval of health claims.
Suppose a study (randomised, controlled and double-blind)
has been performed in healthy adult volunteers (50–70 years
old) who consume either the (imaginary) probiotic strain
‘Lactobacillus prosana’ or placebo for 30 d. Comparison of
blood natural killer (NK) cell activity measured before and
after the intervention shows a significant increase in NK
activity in the probiotic group and no change in the placebo
group. An independent replication of this study has confirmed
the results. What health effect can be claimed?
(1) L. prosana enhances NK cell activity.
(2) L. prosana improves natural immunity against viruses.
(3) L. prosana protects against viral infections.
From the scientific perspective, the first answer is the
correct one, but from a regulatory perspective, all answers to
this hypothetical multiple choice question are wrong. EFSA
has listed the regulatory issues that should be addressed when
making a health claim. Minimally these are (1) characterisation
of the probiotic product, (2) substantiation of the immune
health benefit, i.e. demonstration that the biomarker measured
contributes to an improvement of the overall functioning of the
immune system and (3) extrapolation to the general healthy
population. These regulatory issues, which are required for
bridging probiotics science and probiotics marketing, have
been pivotal in the evaluation of health claims for probiotics.
Characterisation of probiotic bacteria
It is a well-established fact that the biological effects of probio-
tics are strain specific. Stig Bengmark has made this very clear
in his statement that the (genetic) difference between one pro-
biotic bacterium and the other is larger than the difference
between a man and a goldfish. The success (or failure) of
one strain cannot be extrapolated to another strain (or strains).
The strain-specific benefits of probiotics thus emphasises the
need for proper strain identification(6).
Unambiguous species identification can be performed
by 16S rRNA gene sequence analysis and by DNA–DNA
hybridisation techniques. For strain identification, different
molecular microbiological typing techniques can be applied
such as pulsed-field gel electrophoresis, amplified fragment
length polymorphism or multilocus sequence typing. It
would be helpful if the regulatory authorities, together with
organisations such as the International Life Science Institute,
the International Dairy Federation, the European Food and
Feed Culture Association, and others in the scientific commu-
nity could assign one, or several, of these techniques as
necessary and sufficient for strain identification. Moreover,
genomic sequence technology is developing rapidly and will
become available soon and can facilitate strain identification.
For both scientific and regulatory purposes, bacteria should
be named according to the international nomenclature rules,
and fantasy names such as L. prosana are not allowed.
Furthermore, strains should be deposited at internationally
recognised culture collections with access numbers. In future
scientific publications, these details on the characterisation
and identification of the probiotic strains could already be
included (or referred to as supplementary data).
The techniques used for strain identification generate a ‘fin-
gerprint’ of a particular bacterial strain. These techniques do
not provide information on the structure or sequence of func-
tionality encoding genes. Thus, the genetic fingerprint only
serves regulatory purposes and bears no relation to function-
ality. Strains that appear to differ in molecular typing may
have identical functionality encoding genes(4). On the other
hand, the mere presence of a given gene is also insufficient to
ascertain a specific health benefit, as there is a ‘carrier’ impact

















of the strain, i.e. the same gene in different species may not lead
to an identical effect. Unfortunately, with a few exceptions(7,8),
the genes that determine or underlie the health benefit deliv-
ered by specific probiotic strains have not been identified to
date. There are no in vitro assays or even animal models,
which allow to establish a probiotic effect, but they might be
used to characterise the probiotic or to establish possible mech-
anisms of action. Demonstration of a beneficial effect of a given
probiotic strain can only be demonstrated in functional in vivo
studies. The implication is that every new strain or combination
of strains should be subjected to costly and lengthy clinical
studies to substantiate a health claim.
Health benefits in healthy people
The WHO has defined health as a state of complete physical,
mental and social well-being and not merely the absence of
disease or infirmity(9). This definition was proposed in 1948
at the inauguration of the WHO and has not been revised in
over 60 years.
In relation to health claims, the operational value of the WHO
definition is limited because it leaves no room for improvement
(a state of complete . . . well-being), and thus it would be
impossible for probiotics or any other nutrient to have a
beneficial effect in healthy individuals. The present definition
of health as a state lacks the temporal dimension and does not
address its dynamics. Yet, the health state will have its oscil-
lations, depending on changes in intrinsic factors (human
biology and lifestyle) and extrinsic factors (the environment
and healthcare services). Thus, in order to maintain health, con-
stant adaptation and response to challenge are required, which
depends on the resilience capacity (i.e. the capacity to return to
a homeostatic state) of the individual subject. An example is
antibiotic-associated diarrhoea, which will develop when the
resilience capacity is insufficient to maintain the equilibrium
of the gut microbiota (see also below). Outside the food and
nutrition area, the term ‘enhancement’ is used for methods to
improve the healthy body. Compounds that improve brain
function, such as nootropics, referred to as smart drugs, are
examples of enhancement. The whole field of preventive medi-
cine, such as childhood vaccination programmes and addition
of fluoride to drinking-water, to prevent caries and maintain
oral health, deals with the maintenance of health. The objective
of vaccination is to confer protective immunity (by stimulation
of the immune system) against an otherwise severe infectious
disease. Vaccines are administered to healthy children and pro-
tective effects are evident at the population level as a reduction
in the incidence of disease, in most cases by.98 %. For an indi-
vidual child, it is more difficult to estimate whether the child is
benefited from the herd immunity or whether the child’s
immune system could have been strong enough to combat
the infection in question.
Function of the immune system in relation to
human health
The function of the immune system is to protect against infec-
tious diseases. In order to fulfil this function, the immune
system operates at two levels. The innate immune response
is activated within minutes or hours of encountering the anti-
gen, and the specific adaptive immunity takes days or weeks
to develop and act. Phagocytes and NK cells produce cyto-
kines and chemokines, which together with complement
lead to the innate responses. Innate immunity orchestrates
adaptive immunity that consists of B and T lymphocytes respon-
sible for antibody production and generation of cytotoxic T lym-
phocytes. The capacity of the adaptive immune system to
develop immunological memory is utilised in vaccination to
prevent infectious diseases. Under normal physiological con-
ditions, the immune system protects the individual against
most infections. The function of the immune system can be tem-
porarily impaired due to intrinsic or extrinsic factors, can be per-
manently weakened for example in the elderly and is not yet fully
mature during infancy. Even short periods of reduced immune
competence can compromise the ability to fight infections.
Probiotics have the capacity to stimulate various compone-
nts of the immune system. In 2005, Albers et al.(10) identified
twenty-eight different groups of markers to measure immuno-
modulation in human nutrition intervention studies. Ig levels
in serum and at mucosal surfaces, systemic cytokine concen-
trations, number and activity of phagocytic cells and NK
cells are among the endpoints most often studied. However,
none of these biomarkers are by themselves indicative
for the overall immune status of an individual. Therefore, it
is difficult to predict whether for instance a 25 % increase in
the concentration of secretory IgA in the mucosal surfaces
of the upper respiratory tract really would confer better
protection against influenza virus infection. This is the
reason why claims such as ‘strengthens the immune system’
are considered too vague or even meaningless, unless they
relate to a more specific health claim such as ‘reduces the
risk of common cold episodes during winter season’.
There is a clear gap between the scientific understanding of
the immune markers and immune system and the regulatory
requirement for measuring the effect on immune health.
In order to be able to substantiate an immune health claim
appropriately, a list of markers relevant for immunity pub-
lished by EFSA would be of great importance. For the time
being, double-blind placebo-controlled (DBPC) clinical trials
on the reduction of disease risk that also incorporate
immune markers would be required.
In order to demonstrate that probiotics can actually reduce
the risk for gastrointestinal and respiratory infections, DBPC
clinical trials are required. To that end, in most cases, the
study population consists of subjects with an increased risk
of infection, namely the (very) young and the (very) old.
The frequency of respiratory tract infections in otherwise
healthy toddlers in day care centres and the frequency of
flu-like infections during the winter season in otherwise
healthy elderly have been shown to be reduced by probio-
tics(11). The two requirements in the regulatory procedures,
i.e. the demonstration of the causality of the probiotic effect
on the reduction of disease risk and the extrapolation of the
observed effects to the general population then become the
hurdles for obtaining health claims. How to demonstrate that
the components of the immune system that contribute to

















protection against infection, e.g. a rhinovirus, are stimulated
by probiotics? In future clinical studies, biomarkers of the
immune system should be included, which then can be used
as supporting evidence to demonstrate the causality of the
beneficial effect(11). The choice of biomarkers or risk factors
will depend on the specific clinical effect. For the aforemen-
tioned example of rhinovirus infection, these would include
biomarkers of the acquired cellular immune system. It
should be noted that from a scientific perspective the focus
on underlying mechanisms of probiotic health effects is evi-
dent. From a regulatory perspective, the need for any demon-
stration of mechanisms could be questioned. Yet, from
published opinions, it is clear that the NDA panel needs to
be convinced of a cause and effect relationship between
intake of probiotics and claimed health benefit.
Compared with other food and nutritional ingredients,
demonstration of the mechanism of the probiotic effect is
hampered by the biological complexity of this ingredient. In
theory, the effect can be mediated by the complete organism
or by specific components of the bacterium (e.g. CpG DNA,
cell envelope or secreted proteins, capsular polysaccharides
and metabolites). This sharply contrasts for instance with
the immunomodulatory effects of a single molecule, such as
vitamin D (see later).
Gut microbiota in relation to human health
A number of beneficial effects of probiotics dealing with gut
health have been evaluated in Cochrane reviews. These
meta-analyses have demonstrated the effect of probiotics
on the prevention and treatment of antibiotic-associated
diarrhoea(12), necrotising enterocolitis(13) and induction and
maintenance of the remission time in pouchitis(14). Another
beneficial effect that has been demonstrated is prevention of
traveller’s diarrhoea(15). Gut health also involves bowel func-
tion (transit time, frequency of bowel movements, quality of
stools, etc), and improvement of bowel functions within the
normal range is considered to be beneficial to human health.
Apart from traveller’s diarrhoea, all of the studies mentioned
earlier have been performed in individuals with a temporary
or permanent impaired gut health. According to the EFSA cri-
teria, patient studies may be used to substantiate health claims
for the general population, but these are evaluated on a case-
by-case basis. The exception is irritable bowel syndrome
(IBS). According to the EFSA NDA panel, episodes of abdomi-
nal pain or discomfort occur both in healthy people and in
individuals suffering from IBS, the difference being the
higher frequency and greater severity of the symptoms in
IBS. IBS patients are generally considered to be an appropriate
study group to support claims on gastrointestinal discomfort
intended for the general population. A similar case could be
made for antibiotic-associated diarrhoea: in many cases for
which antibiotics are prescribed, gut health per se is not
affected or impaired. The unwanted side effect of antibiotics
can be prevented by probiotics, which therefore can be con-
sidered as maintenance of gut health.
Digestive health requires a ‘healthy’ gut microbiota, but
what is a healthy gut microbiota? Even if we take this to be
the gut microbiota of healthy individuals, the answer remains
ambiguous. For the fifty-seven most common bacterial
species identified by metagenome sequence analysis in the
human gut, the inter-individual variability of abundance is
between 12- and 2187-fold(16). For less abundant bacteria, the
inter-individual variation may be even greater. Moreover, the
intestinal microbiota also changes in time as was illustrated
recently in a study, in which age groups up to 100 years were
compared(17). Therefore, depending on the degree of differen-
tiation of the technique, the composition of gut microbiota may
be a unique individual characteristic, as has been shown
previously(18). However, a clearly distinct composition of gut
microbiota, both compared with healthy individuals and
between the two diseases, is found in inflammatory bowel
disease (ulcerative colitis and Crohn’s disease)(16). Hence, it
may be possible to distinguish an ‘unhealthy’ from a ‘healthy’
gut microbiota. While no direct health benefit can be attributed
to a global increase in bifidobacteria, reducing specific patho-
gen carriage can be considered as beneficial. Gut microbiota
biomarkers clearly need to be correlated with (and validated
by) clinical endpoints.
The gut microbiota is of crucial importance for the correct
development and function of the mucosal immune system. In
a series of landmark publications(7,19,20), Dennis Kasper’s
group has demonstrated that the capsular polysaccharide poly-
saccharide A of Bacteroides fragilis is indispensable for normal
development of mucosal T lymphocytes and control of exper-
imental colitis. In allergic diseases, the abnormalities in the com-
position of the gut microbiota precede the clinical expression of
the disease(21), although the cause and effect relationship has
not been demonstrated yet. When evaluating totally of the evi-
dence for the beneficial effects of probiotics on immune-
mediated diseases, modulation of gut microbiota composition
thus appears to be an important component. More research in
human subjects, using state of the art microbiological method-
ologies, will be needed to confirm the role of probiotics in the
improvement of gut microbiota equilibrium.
What can be learned from the scientific opinions of
regulatory authorities thus far?
At this moment, there are more examples of negative opinions
by the NDA of EFSA than positive ones, and the key factors for
a successful health claim application of a given probiotic strain
therefore cannot be extracted. Evaluation of all published
opinions shows that applications can be rejected on the sole
argument of insufficient characterisation of the product or
the ingredient (e.g. the probiotic strain). A recently published
EFSA opinion(22) lists a series of bacteria for which the health
claims were dismissed on those grounds (see also the above
section on Characterisation of probiotic bacteria). In many
instances, the necessary information was in hand, but it was
unclear that these data were requested in the dossier for sub-
mission. Whether approval of health claims under article 13.5,
allowing for inclusion of proprietary data, also requires
equally detailed strain identification is to be expected.
Health claims for (otherwise fully characterised) probiotic
bacteria were further rejected because the submitted scientific

















evidence is considered to be insufficient or irrelevant for the
claim. The NDA panel wants to see the claimed health effect
to be demonstrated in at least two randomised, (placebo) con-
trolled clinical trials.
Important for the evaluation of a health claim is the cause
and effect relationship. The approval of the health claim for
vitamin D can be instructive in this respect. The EFSA panel
has concluded that a cause and effect relationship has been
established between the dietary intake of vitamin D and contri-
bution to the normal function of the immune system and
healthy inflammatory response(23). From the evidence sub-
mitted (in the form of three review papers(24–26)), it appears
that vitamin D has variable effects on different components of
the immune system. Vitamin D enhances the killing of the intra-
cellular micro-organisms Mycobacterium tuberculosis by
monocytes because vitamin D induces cathelicidin, a potent
antimicrobial protein(24). Vitamin D also inhibits the clearance
of Listeria monocytogenes, which is another intracellular
micro-organism(25). Vitamin D has been shown to inhibit
a number of components of the adaptive immune system,
including T lymphocyte proliferation and antibody production.
These effects can be beneficial for reducing the incidence of
autoimmune diseases but are unwanted in the case of infectious
diseases.
The two strong points for vitamin D are that the compound
is very well characterised, and that the receptors for vitamin D
are expressed by cells of the immune system. The effects
of the interaction between vitamin D and its receptor on
lymphocytes/phagocytes are variable (sometimes stimulatory
and sometimes inhibitory), but the conclusion that vitamin D
contributes to the normal function of the immune system was
accepted by the NDA panel. These strong points for vitamin D
are impossible to reach for probiotics: bacteria are complex
biological ‘products’, and extensive molecular characterisation
will not change that. Receptors for probiotics could be at best
for components of probiotics. For a number of strains, it has
been demonstrated now that the probiotic bacteria can bind
to receptors on cells of the immune system including dendritic
cells(27). Therefore, emphasis on the physical interaction of
probiotic bacteria with relevant receptors on cells of the
immune system will be important to bring additional evidence
on the underlying mechanisms of immunoregulatory effects
of probiotics.
Conclusions and recommendations
Currently, there is a gap between the point where the bio-
medical science ends (with the publication of a paper in a
scientific journal) and the point where the business begins
(with the claim for a health benefit). Regulatory science that
links the regulatory requirements of (in this case) probiotic
product development to the science that ensures safety and
functionality of probiotics will be needed to close this gap.
Because health claim approval requires both regulatory and
basic sciences, both disciplines would benefit from a dialogue.
One of the issues that needs to be discussed is the assessment
of the quality of clinical studies, because many peer-reviewed
studies are considered weak or even insufficient from the
regulatory point of view. However, clear-cut criteria defining
gut health and immune health are lacking, and EFSA
apparently works on a case-by-case scenario. For the future,
it will be important to integrate the regulatory considerations
in basic and clinical research. Characterisation of the probiotic
product under study (including food matrix and background
diet when appropriate) and selection criteria for the study
population would be two obvious items to start with. Finally,
a dialogue would be helpful to prevent that health claims for
probiotics are lost in translation during the rewording of the
conclusions from scientific research into a message that can
be understood by the ‘average consumer’.
The substantiation of the beneficial effects of probiotics
into health claims that are approved by regulatory authorities
and understood by the consumers is a joint responsibility of
scientists, regulatory authorities, food and nutrition industry
and consumers. An open dialogue and reaching consensus
on a list of validated biomarkers for immune and gut health
could be the first step in this process.
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